Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes

Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a select...

Full description

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 108; no. 2; pp. 522 - 531
Main Authors Fischer, Melissa A., Song, Yuanbin, Arrate, Maria P., Gbyli, Rana, Villaume, Matthew T., Smith, Brianna N., Childress, Merrida A., Stricker, Thomas P., Halene, Stephanie, Savona, Michael R.
Format Journal Article
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.02.2023
Ferrata Storti Foundation
Subjects
Animals
Apoptosis
Bridged Bicyclo Compounds, Heterocyclic - pharmacology
Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
Cell Line, Tumor
Disease Models, Animal
Leukemia, Myeloid, Acute - genetics
Mice
Myelodysplastic Syndromes
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - genetics
Myelodysplastic Syndromes - metabolism
Myeloid Cell Leukemia Sequence 1 Protein - metabolism
Proto-Oncogene Proteins c-bcl-2
Online AccessGet full text

Cover

Abstract Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma- 2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic proteins BCL-XL and induced myeloid cell leukemia 1 (MCL1) are implicated in leukemia survival, and upregulation of MCL1 is seen in VEN-resistant AML and MDS. We determined in vitro sensitivity of MDS patient samples to selective inhibitors of BCL2, BCL-XL and MCL1. While VEN response positively correlated with MDS with excess blasts, all MDS subtypes responded to MCL1 inhibition. Treatment with combined VEN + MCL1 inhibtion was synergistic in all MDS subtypes without significant injury to normal hematopoiesis and reduced MDS engraftment in MISTRG6 mice, supporting the pursuit of clinical trials with combined BCL2 + MCL1 inhibition in MDS.
AbstractList Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma- 2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic proteins BCL-XL and induced myeloid cell leukemia 1 (MCL1) are implicated in leukemia survival, and upregulation of MCL1 is seen in VEN-resistant AML and MDS. We determined in vitro sensitivity of MDS patient samples to selective inhibitors of BCL2, BCL-XL and MCL1. While VEN response positively correlated with MDS with excess blasts, all MDS subtypes responded to MCL1 inhibition. Treatment with combined VEN + MCL1 inhibtion was synergistic in all MDS subtypes without significant injury to normal hematopoiesis and reduced MDS engraftment in MISTRG6 mice, supporting the pursuit of clinical trials with combined BCL2 + MCL1 inhibition in MDS.
Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma-2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic proteins BCL-X L and induced myeloid cell leukemia 1 (MCL1) are implicated in leukemia survival, and upregulation of MCL1 is seen in VEN-resistant AML and MDS. We determined in vitro sensitivity of MDS patient samples to selective inhibitors of BCL2, BCL-X L and MCL1. While VEN response positively correlated with MDS with excess blasts, all MDS subtypes responded to MCL1 inhibition. Treatment with combined VEN + MCL1 inhibtion was synergistic in all MDS subtypes without significant injury to normal hematopoiesis and reduced MDS engraftment in MISTRG6 mice, supporting the pursuit of clinical trials with combined BCL2 + MCL1 inhibition in MDS.
Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma- 2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic proteins BCL-XL and induced myeloid cell leukemia 1 (MCL1) are implicated in leukemia survival, and upregulation of MCL1 is seen in VEN-resistant AML and MDS. We determined in vitro sensitivity of MDS patient samples to selective inhibitors of BCL2, BCL-XL and MCL1. While VEN response positively correlated with MDS with excess blasts, all MDS subtypes responded to MCL1 inhibition. Treatment with combined VEN + MCL1 inhibtion was synergistic in all MDS subtypes without significant injury to normal hematopoiesis and reduced MDS engraftment in MISTRG6 mice, supporting the pursuit of clinical trials with combined BCL2 + MCL1 inhibition in MDS.Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma- 2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic proteins BCL-XL and induced myeloid cell leukemia 1 (MCL1) are implicated in leukemia survival, and upregulation of MCL1 is seen in VEN-resistant AML and MDS. We determined in vitro sensitivity of MDS patient samples to selective inhibitors of BCL2, BCL-XL and MCL1. While VEN response positively correlated with MDS with excess blasts, all MDS subtypes responded to MCL1 inhibition. Treatment with combined VEN + MCL1 inhibtion was synergistic in all MDS subtypes without significant injury to normal hematopoiesis and reduced MDS engraftment in MISTRG6 mice, supporting the pursuit of clinical trials with combined BCL2 + MCL1 inhibition in MDS.
Author Song, Yuanbin
Fischer, Melissa A.
Savona, Michael R.
Villaume, Matthew T.
Smith, Brianna N.
Halene, Stephanie
Childress, Merrida A.
Gbyli, Rana
Arrate, Maria P.
Stricker, Thomas P.
AuthorAffiliation 2 Cancer Biology Program, Vanderbilt University School of Medicine , Nashville, TN, USA
3 Department of Hematologic Oncology, Sun Yat-sen University Cancer Center , State Key Laboratory of Oncology in South China , Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
8 Center for Immunobiology, Vanderbilt University School of Medicine , Nashville, TN, USA
5 Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, TN, USA
7 Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine , Nashville, TN, USA
4 Smilow Cancer Center, Yale University School of Medicine , New Haven, CT, USA
1 Department of Medicine, Vanderbilt University School of Medicine , Nashville, TN, USA
6 Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine , Nashville, TN, USA
AuthorAffiliation_xml – name: 7 Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine , Nashville, TN, USA
– name: 1 Department of Medicine, Vanderbilt University School of Medicine , Nashville, TN, USA
– name: 3 Department of Hematologic Oncology, Sun Yat-sen University Cancer Center , State Key Laboratory of Oncology in South China , Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
– name: 5 Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, TN, USA
– name: 8 Center for Immunobiology, Vanderbilt University School of Medicine , Nashville, TN, USA
– name: 4 Smilow Cancer Center, Yale University School of Medicine , New Haven, CT, USA
– name: 6 Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine , Nashville, TN, USA
– name: 2 Cancer Biology Program, Vanderbilt University School of Medicine , Nashville, TN, USA
Author_xml – sequence: 1
  givenname: Melissa A.
  surname: Fischer
  fullname: Fischer, Melissa A.
– sequence: 2
  givenname: Yuanbin
  surname: Song
  fullname: Song, Yuanbin
– sequence: 3
  givenname: Maria P.
  surname: Arrate
  fullname: Arrate, Maria P.
– sequence: 4
  givenname: Rana
  surname: Gbyli
  fullname: Gbyli, Rana
– sequence: 5
  givenname: Matthew T.
  surname: Villaume
  fullname: Villaume, Matthew T.
– sequence: 6
  givenname: Brianna N.
  surname: Smith
  fullname: Smith, Brianna N.
– sequence: 7
  givenname: Merrida A.
  surname: Childress
  fullname: Childress, Merrida A.
– sequence: 8
  givenname: Thomas P.
  surname: Stricker
  fullname: Stricker, Thomas P.
– sequence: 9
  givenname: Stephanie
  surname: Halene
  fullname: Halene, Stephanie
– sequence: 10
  givenname: Michael R.
  surname: Savona
  fullname: Savona, Michael R.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35979721$$D View this record in MEDLINE/PubMed
BookMark eNp9kktvEzEUhS1URNPCP0DISzYJfo7HLJBQxKNSEAtgbXnsO42Lxw72JCL_nhnSIMqClSX7nO9c654rdJFyAoSeU7LinIlXWwuDHXNcMcLYirWk4fQRWlCp2bJVjF6gBeGaLBui2kt0VesdIYxorZ6gSy610pNmgb5_gQhuDAfAIW1DF8aQE849_rTeUJwPUFweoOIDJBizi_YnLlBDHW1yswVbPOxLSICH7CHOzuEIMftj3UVbx-BwPSZfZshT9Li3scKz-_MafXv_7uv643Lz-cPN-u1m6YQS41ICUKedJI6w1vUNeNl52XJKWse9Z6S1nehEI7lyQgjpuukvRFNBRO8UNPwa3Zy4Pts7sythsOVosg3m90Uut8aWabIIRuqGckE1MMeE4roVfa-thLZRSnqtJtabE2u37wbwDtJYbHwAffiSwtbc5oPRrSaEswnw8h5Q8o891NEMoTqI0SbI-2qYInMsYXySvvg760_IeVuT4PVJ4EqutUBvXBjtvLEpOkRDiZmrYc7VMHM1zKkak1n8Yz7z_2v7BTJawVY
CitedBy_id crossref_primary_10_1038_s41419_024_06866_5
crossref_primary_10_1016_j_leukres_2024_107602
crossref_primary_10_1016_j_xcrm_2023_100940
crossref_primary_10_1016_j_medidd_2024_100199
crossref_primary_10_1080_14737140_2024_2414071
crossref_primary_10_1371_journal_pone_0307662
Cites_doi 10.1016/S0145-2126(02)00221-7
10.18632/oncotarget.24538
10.1182/blood-2003-09-3192
10.1182/blood-2016-04-709584
10.1016/0145-2126(92)90006-S
10.1093/bioinformatics/btx162
10.1158/2159-8290.CD-16-0313
10.1038/leu.2013.372
10.1182/blood.V96.12.3932
10.1158/2159-8290.CD-17-0151
10.1182/blood-2018-08-868752
10.1182/blood-2019-124994
10.18632/oncotarget.24775
10.1093/nar/gkaa216
10.1016/S1535-6108(02)00127-7
10.1038/leu.2010.158
10.1038/leu.2017.172
10.3324/haematol.2017.183202
10.1182/blood.2019003988
10.1182/blood-2015-10-676452
10.1111/j.1365-2141.1994.tb04904.x
10.1038/leu.2015.179
10.1002/ajh.25146
10.1016/j.csbj.2015.09.001
10.1016/j.stem.2014.02.014
10.1200/JCO.18.01600
10.1182/blood-2014-03-560227
10.1038/s41375-018-0261-3
10.1158/2159-8290.CD-19-0125
10.1158/2159-8290.CD-19-0710
10.1016/j.cell.2011.02.013
10.1038/s41467-018-08166-x
10.1016/j.molcel.2016.02.019
10.1182/blood-2014-10-604975
10.3109/10428190109064605
10.1158/2159-8290.CD-19-0117
10.1038/nm.4202
10.1158/2159-8290.CD-18-0140
10.1182/bloodadvances.2020001482
10.3324/haematol.2010.027557
10.1016/j.htct.2019.12.002
10.1016/j.leukres.2009.03.005
10.1038/leu.2010.156
ContentType Journal Article
Copyright Copyright© 2023 Ferrata Storti Foundation
Copyright_xml – notice: Copyright© 2023 Ferrata Storti Foundation
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3324/haematol.2022.280631
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1592-8721
EndPage 531
ExternalDocumentID oai_doaj_org_article_59613419e2c2473984ff9a5e86775d97
PMC9890032
35979721
10_3324_haematol_2022_280631
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P30 CA068485
– fundername: NIDDK NIH HHS
  grantid: R01 DK102792
– fundername: NCI NIH HHS
  grantid: T32 CA217834
– fundername: NCI NIH HHS
  grantid: R01 CA262287
– fundername: NIDDK NIH HHS
  grantid: U54 DK106857
– fundername: NCATS NIH HHS
  grantid: UL1 TR001863
– fundername: NCATS NIH HHS
  grantid: UL1 TR000445
– fundername: NCI NIH HHS
  grantid: K12 CA090625
GroupedDBID ---
29I
2WC
53G
5GY
5RE
5VS
AAFWJ
AAYXX
ADBBV
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BTFSW
CITATION
CS3
DIK
E3Z
EBS
EJD
F5P
FRP
GROUPED_DOAJ
H13
HYE
KQ8
OK1
OVT
P2P
RHI
RNS
RPM
SJN
TFS
TR2
W8F
WOQ
WOW
CGR
CUY
CVF
ECM
EIF
M~E
NPM
RHF
SV3
7X8
5PM
ID FETCH-LOGICAL-c474t-5ee1c9c50c028cf6ed5bd583108c3dd208ab4b46537c4445cb797091404fc7e63
IEDL.DBID DOA
ISSN 0390-6078
1592-8721
IngestDate Wed Aug 27 01:30:03 EDT 2025
Thu Aug 21 18:38:21 EDT 2025
Fri Jul 11 04:05:27 EDT 2025
Thu Jan 02 22:31:41 EST 2025
Thu Apr 24 23:06:18 EDT 2025
Tue Jul 01 04:22:27 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License http://creativecommons.org/licenses/by-nc/4.0
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c474t-5ee1c9c50c028cf6ed5bd583108c3dd208ab4b46537c4445cb797091404fc7e63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
MRS has served on consultancy/advisory board/data safety monitoring committees for Abbvie, BMS, CTI, Forma, Geron, Karyopharm, Novartis, Ryvu, Sierra Oncology, Takeda, Taiho TG Therapeutics; has equity in Karyopharm; and his institution has received research funding from ALX Oncology, Incyte, Takeda, and TG Therapeutics. SH serves on the advisory board of FORMA Therapeutics.
Disclosures
Contributions
MAF, YS, and RG designed and performed experiments. MPA, and MTV performed experiments. MAF, YS, RG, MPA, MTV, MAC, BNS, TPS, SH, and MRS analyzed data. MAF and MRS performed statistical analysis and wrote the manuscript. SH and MRS designed and supervised the study. All authors reviewed and edited drafts of the manuscript and approved the final version of the manuscript.
Data-sharing statement
Not applicable as data generated in this study have been included in the published article.
OpenAccessLink https://doaj.org/article/59613419e2c2473984ff9a5e86775d97
PMID 35979721
PQID 2703984023
PQPubID 23479
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_59613419e2c2473984ff9a5e86775d97
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9890032
proquest_miscellaneous_2703984023
pubmed_primary_35979721
crossref_citationtrail_10_3324_haematol_2022_280631
crossref_primary_10_3324_haematol_2022_280631
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-02-01
PublicationDateYYYYMMDD 2023-02-01
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-01
  day: 01
PublicationDecade 2020
PublicationPlace Italy
PublicationPlace_xml – name: Italy
PublicationTitle Haematologica (Roma)
PublicationTitleAlternate Haematologica
PublicationYear 2023
Publisher Fondazione Ferrata Storti
Ferrata Storti Foundation
Publisher_xml – name: Fondazione Ferrata Storti
– name: Ferrata Storti Foundation
References 44621
44620
44601
44623
44600
44622
44607
44629
44606
44628
44609
44608
44603
44625
44602
44624
44605
44627
44604
44626
44599
44610
44632
44598
44631
44612
44634
44611
44633
44597
44630
44596
44618
44617
44619
44614
44636
44613
44635
44616
44638
44615
44637
References_xml – ident: 44632
  doi: 10.1016/S0145-2126(02)00221-7
– ident: 44636
  doi: 10.18632/oncotarget.24538
– ident: 44631
  doi: 10.1182/blood-2003-09-3192
– ident: 44625
  doi: 10.1182/blood-2016-04-709584
– ident: 44623
  doi: 10.1016/0145-2126(92)90006-S
– ident: 44611
  doi: 10.1093/bioinformatics/btx162
– ident: 44609
  doi: 10.1158/2159-8290.CD-16-0313
– ident: 44627
  doi: 10.1038/leu.2013.372
– ident: 44597
  doi: 10.1182/blood.V96.12.3932
– ident: 44613
  doi: 10.1158/2159-8290.CD-17-0151
– ident: 44603
  doi: 10.1182/blood-2018-08-868752
– ident: 44606
  doi: 10.1182/blood-2019-124994
– ident: 44596
  doi: 10.18632/oncotarget.24775
– ident: 44612
  doi: 10.1093/nar/gkaa216
– ident: 44601
  doi: 10.1016/S1535-6108(02)00127-7
– ident: 44633
  doi: 10.1038/leu.2010.158
– ident: 44637
  doi: 10.1038/leu.2017.172
– ident: 44634
  doi: 10.3324/haematol.2017.183202
– ident: 44617
  doi: 10.1182/blood.2019003988
– ident: 44622
  doi: 10.1182/blood-2015-10-676452
– ident: 44628
  doi: 10.1111/j.1365-2141.1994.tb04904.x
– ident: 44599
  doi: 10.1038/leu.2015.179
– ident: 44616
  doi: 10.1002/ajh.25146
– ident: 44610
  doi: 10.1016/j.csbj.2015.09.001
– ident: 44635
  doi: 10.1016/j.stem.2014.02.014
– ident: 44604
  doi: 10.1200/JCO.18.01600
– ident: 44614
  doi: 10.1182/blood-2014-03-560227
– ident: 44638
  doi: 10.1038/s41375-018-0261-3
– ident: 44619
  doi: 10.1158/2159-8290.CD-19-0125
– ident: 44615
  doi: 10.1158/2159-8290.CD-19-0710
– ident: 44602
  doi: 10.1016/j.cell.2011.02.013
– ident: 44620
  doi: 10.1038/s41467-018-08166-x
– ident: 44600
  doi: 10.1016/j.molcel.2016.02.019
– ident: 44607
  doi: 10.1182/blood-2014-10-604975
– ident: 44598
  doi: 10.3109/10428190109064605
– ident: 44618
  doi: 10.1158/2159-8290.CD-19-0117
– ident: 44621
  doi: 10.1038/nm.4202
– ident: 44608
  doi: 10.1158/2159-8290.CD-18-0140
– ident: 44605
  doi: 10.1182/bloodadvances.2020001482
– ident: 44629
  doi: 10.3324/haematol.2010.027557
– ident: 44624
  doi: 10.1016/j.htct.2019.12.002
– ident: 44626
  doi: 10.1016/j.leukres.2009.03.005
– ident: 44630
  doi: 10.1038/leu.2010.156
SSID ssj0020997
Score 2.4195848
Snippet Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 522
SubjectTerms Animals
Apoptosis
Bridged Bicyclo Compounds, Heterocyclic - pharmacology
Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
Cell Line, Tumor
Disease Models, Animal
Leukemia, Myeloid, Acute - genetics
Mice
Myelodysplastic Syndromes
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - genetics
Myelodysplastic Syndromes - metabolism
Myeloid Cell Leukemia Sequence 1 Protein - metabolism
Proto-Oncogene Proteins c-bcl-2
Title Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes
URI https://www.ncbi.nlm.nih.gov/pubmed/35979721
https://www.proquest.com/docview/2703984023
https://pubmed.ncbi.nlm.nih.gov/PMC9890032
https://doaj.org/article/59613419e2c2473984ff9a5e86775d97
Volume 108
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JLaZI-3EdQofTmxtbDso5paAil20sbyE1IY5ldumuH7ga6_z4zsr1kSyGXXm0JiZmRNM9vGPvQRB9LDTIvA9S50lDlXkvIvS98ARBqGah2ePa9urxSX6_19b1WX5QTNsADD4Q71bZKmGNRgFBG2lq1rfU6Eg6bbmyqI8c3bzKmRlOL6kFT_MCicYSv4FA0J1F7OJ17AkPtKewgxCcKLMpy71FK2P3_Ujj_zpu89xBdPGNPRw2Snw07P2SPYnfEjs86XG215R95yulMzvIj9ng2hs6P2a8fqeMNXm580c0XIaVq8b7ls_NvJadETpS9uOZ0-W16WPo_HC1x0i5RLHAK93xFnvnIU_McmrnaxmXfbNc3qIHjZviEfrB-zq4uvvw8v8zHTgs5KKM2uY6xBAu6AFQ3oK1io0OjqQdZDbJpRFH7oAJBsRlQCjkajDVIdVWoFkys5At20PVdfMV4MMFGGU2JHFJQtL4wgkKNUQhbNsJnTE6kdjDCkFM3jKVDc4QY5CYGOWKQGxiUsXw362aA4Xhg_Gfi4m4sgWinDyhabhQt95BoZez9JAMODx1FUnwX-9u1E3hP4nDUdzL2cpCJ3VISTTSCRMqY2ZOWvb3s_-kW8wTsbWvyK4vX_2Pzb9gTpIccEszfsoPN79v4DvWnTThJR-UkObbuAPMlGS4
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Selective+inhibition+of+MCL1+overcomes+venetoclax+resistance+in+a+murine+model+of+myelodysplastic+syndromes&rft.jtitle=Haematologica+%28Roma%29&rft.au=Fischer%2C+Melissa+A.&rft.au=Song%2C+Yuanbin&rft.au=Arrate%2C+Maria+P.&rft.au=Gbyli%2C+Rana&rft.date=2023-02-01&rft.issn=0390-6078&rft.eissn=1592-8721&rft.volume=108&rft.issue=2&rft.spage=522&rft.epage=531&rft_id=info:doi/10.3324%2Fhaematol.2022.280631&rft.externalDBID=n%2Fa&rft.externalDocID=10_3324_haematol_2022_280631
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0390-6078&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0390-6078&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0390-6078&client=summon